Montana
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
Indigenous Peoples in Montana are most likely to be diagnosed with lung cancer.
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases is 46.5 and significantly lower than the national rate of 53.6.
- Montana ranks 12th among all states, placing it in the above average tier.
- Over the last five years, the rate of new cases did not change signficantly.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Montana is 27.7%, which is not significantly different than the national rate of 28.4%.
- It ranks 24th among the 42 states with survival data, placing it in the average tier.
- Over the last five years, the survival rate in Montana improved by 34%.
Early Diagnosis:
- 28.7% of cases are caught at an early stage, which is not significantly different than the national rate of 27.4%.
- It ranks 15th among the 47 states with data on diagnosis at an early stage, placing it in the above average tier.
- Over the last five years, the early diagnosis rate in Montana did not change significantly.
Lung Cancer Treatment
Surgical Treatment:
- Montana ranked 24th (out of the 47 states with available data) with 19.7% of cases undergoing surgery as part of the first course of treatment.
- This is not significantly different than the national rate of 20.7% and puts Montana in the average tier.
- Over the last five years, the percent of cases undergoing surgery in Montana did not change significantly.
Biomarker Coverage:
- Montana has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of September 2024.
Lack of Treatment:
- Montana ranked 33rd (out of the 47 states with available data) with 22.2% of cases not receiving any treatment.
- This is not significantly different than the national rate of 20.9% and puts Montana in the average tier.
- Over the last five years, the percent of cases receiving no treatment in Montana did not change significantly.
Screening
Screening for High Risk:
- In Montana, 13.2% of those at high risk were screened, which was not significantly different than the national rate of 16.0%.
- It ranks 40th among all states, placing it in the below average tier.
Prevention
Tobacco Use:
- The smoking rate in Montana is 15.2% and not significantly different than the national rate of 12.9%.
- It ranks 36th among all states, placing it in the below average tier.
Radon:
- In Montana, 45.6% of radon tests results were at or above the action level recommended by EPA.
- It ranks 44th among all states, placing it in the bottom tier.
Racial & Ethnic Disparities
Black individuals:
- Lung cancer rates are not available for Black individuals in Montana due to too few cases over the time period to allow for accurate analysis.
Latino individuals:
- The rate of new lung cancer cases is 22.3 per 100,000 population among Latino individuals in Montana, not significantly different than the rate of 28.1 among Latino individuals nationally, and significantly lower than the rate of 45.3 among white individuals in Montana.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Latino individuals in Montana due to too few cases over the time period to allow for accurate analysis.
Asian Americans or Pacific Islanders:
- Lung cancer rates are not available for Asian or Pacific Islander individuals in Montana due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- The rate of new lung cancer cases is 93.5 per 100,000 population among Indigenous Peoples (American Indians/Alaska Natives) in Montana, significantly higher than the rate of 39.9 among Indigenous Peoples nationally, and significantly higher than the rate of 45.3 among white individuals in Montana.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- 25.6% of lung cancer cases are diagnosed at an early stage among Indigenous Peoples (American Indians/Alaska Natives) in Montana, not significantly different than the rate of 24.7% among Indigenous Peoples (American Indians/Alaska Natives) nationally, and not significantly different than the rate of 29.1% among white individuals in Montana.
- 12.8% of Indigenous Peoples (American Indians/Alaska Natives) with lung cancer in Montana underwent surgery, not significantly different than the rate of 16.0% among Indigenous Peoples (American Indians/Alaska Natives) nationally, and significantly lower than the rate of 20.2% among white individuals in Montana.
- 27.6% of Indigenous Peoples (American Indians/Alaska Natives) with lung cancer in Montana did not receive any treatment, not significantly different than the rate of 24.3% among Indigenous Peoples (American Indians/Alaska Natives) nationally, and significantly higher than the rate of 21.9% among white individuals in Montana.
Summary
Despite the early diagnosis rate in Montana falling into the average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Montana has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Montana falls into the average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: November 12, 2024